Title: Anagrelide represses GATA-1 and FOG-1 expression without interfering with thrombopoietin receptor signal transduction.
Journal: Journal of thrombosis and haemostasis : JTH 20101001
Title: Essential thrombocythemia: past and present.
Journal: Internal and emergency medicine 20091001
Title: [Primary thrombocythemia: diagnosis and therapy].
Journal: Medizinische Klinik (Munich, Germany : 1983) 20060815
Title: Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia.
Journal: Blood 20060601
Title: Anagrelide: a review of its use in the management of essential thrombocythaemia.
Journal: Drugs 20060101
Title: Polycythaemia vera and essential thrombocythaemia: current treatment strategies.
Journal: Drugs 20060101
Title: Primary and secondary thrombocytosis in childhood.
Journal: British journal of haematology 20050401
Title: PDGF-A, PDGF-B, TGFbeta, and bFGF mRNA levels in patients with essential thrombocythemia treated with anagrelide.
Journal: American journal of hematology 20050201
Title: Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia.
Journal: Haematologica 20041101
Title: [Ulcers on the legs and feet: a seldom recognised side effect of hydroxyurea].
Journal: Nederlands tijdschrift voor geneeskunde 20030802
Title: Anagrelide-induced cardiomyopathy.
Journal: Pharmacotherapy 20001001
Title: Pescatore, S.L. and C. Lindley, Anagrelide: a novel agent for the treatment of myeloproliferative disorders. Expert Opin Pharmacother, 2000. 1(3): p. 537-46.
Title: Petrides, P.E., Anagrelide: what was new in 2004 and 2005? Semin Thromb Hemost, 2006. 32(4 Pt 2): p. 399-408.
